v3.26.1
Marketable Securities - Schedule of Marketable Securities Include Investments in Equity Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Short -term:    
Short-term marketable securities $ 4,965 $ 5,417
Long-term:    
Long-term marketable securities 17,967 8,371
DNA [Member]    
Short -term:    
Short-term marketable securities 466 540
Entera [Member]    
Short -term:    
Short-term marketable securities 130 227
Pelthos [Member]    
Short -term:    
Short-term marketable securities [1] 3,013 4,650
Nano’s Put options and written Call options, net [Member]    
Short -term:    
Short-term marketable securities [2] 1,356
Nano [Member]    
Long-term:    
Long-term marketable securities [3] $ 17,967 $ 8,371
[1] During the three months ended March 31, 2026, the Company sold 6,577 shares of Pelthos common stock for aggregate proceeds of $173, resulting in a realized gain of $107 recognized in “financial income (loss), net” in the consolidated statement of comprehensive income (loss).
[2] The written call options and put options on Nano’s shares are held with the same counterparty and are subject to a netting arrangement. Accordingly, they are presented on a net basis in the consolidated balance sheets. As of March 31, 2026, the fair values of written call options and put options were $402 and $1,758, respectively. See Note 18 for further details.
[3] During the three months ended March 31, 2026, the Company purchased 6,401,939 ordinary shares for an aggregate purchase price of $12,258 and sold 1,269,987 shares of Nano common stock for aggregate proceeds of $2,606, resulting in a realized gain of $647 recognized in “financial income (loss), net” in the consolidated statement of comprehensive income (loss). See Note 18 for further details.